Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema
- 346 Downloads
To investigate the association between the characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab treatment for diabetic macular edema (DME) at 3 months from the initial injection.
We retrospectively reviewed 66 eyes of 61 patients with center-involved DME who received three consecutive ranibizumab injections and following as-needed administrations. We evaluated the relationship between visual improvement at 3 months and the preoperative optical coherence tomography (OCT) parameters including hyperreflective foci, heterogeneous OCT reflectivity, mean levels of OCT reflectivity and height of foveal cystoid spaces.
Twenty-three eyes without preoperative hyperreflective foci in the foveal cystoid spaces had significantly greater improvement in the logarithm of the minimum angle of resolution visual acuity (logMAR VA) at 3 months than 43 eyes with foci (P = 0.006). That was similar to the greater reduction in CSF thickness in eyes without lesions after treatment at the same time point (P < 0.001). VA improvement at 3 months was not associated with the height (R = 0.215, P = 0.083) or the reflectivity levels (R = -0.079, P = 0.538) of foveal cystoid spaces. There were no differences in VA changes between eyes with and without heterogeneous reflectivity in foveal cystoid spaces (P = 0.297). Multivariate analyses showed that logMAR VA and the absence of hyperreflective foci in foveal cystoid spaces were associated with VA improvement at 3 months.
Hyperreflective foci in foveal cystoid spaces at baseline predict poorer short-term responsiveness to ranibizumab injections for DME.
KeywordsCystoid spaces Diabetic macular edema Hyperreflective foci Ranibizumab Spectral-domain optical coherence tomography
This study was supported by Grant-in-Aid for Scientific Research of Japan Society for the Promotion of Science (26462637).
Conflicts of interest
T Murakami, None; K. Suzuma, None; A. Uji, None; S. Yoshitake, None; Y. Dodo, None; M. Fujimoto, None; T. Yoshitake, None; Y. Miwa, None; N. Yoshimura, None.
- 13.Hirano T, Toriyama Y, Iesato Y, Imai A, Hirabayashi K, Nagaoka T, et al. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation. Jpn J Ophthalmol. 2017;61:51–60.CrossRefPubMedGoogle Scholar
- 28.Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159(85–91):e1–3.Google Scholar
- 35.Pemp B, Deak G, Prager S, Mitsch C, Lammer J, Schmidinger G, et al. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography. Retina. 2014;34:2407–15.CrossRefPubMedGoogle Scholar